DrGary Wang

A rapid CRISPR-based self-testing platform for early detection of HIV

REBYOTA for the Management of Recurrent Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study

A method for accurate and sensitive detection of HIV drug-resistant minority variants

A Phase 1b/2a, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic

A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)

Gary Wang-IPA Agreement-Waters-FY23

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection

Rapid point-of-care detection of Hepatitis C viral RNA using multiplexed CRISPR/Cas platforms

Investigate the roles of gut microbiome in the differential responses of UTI susceptible women to cranberry juice intake

VA IPA - Jennifer Gollwitzer

Rapid detection of Hepatitis C virus using CRISPR/Cas

Next generation quantitative HCV drug resistance assay

Adaptive Platform Treatment Trial for Outpatients with COVID-19

Analysis of L. lactis strains in murine C. difficile model

Industry Consortium Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

SBIR - A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease.

DRPD-ROF2020: Determine the Metabolic Polymorphisms of American Cranberries to Prevent UTIs in Susceptible Women using an Integrated Metabolome-Microbiome Approach

DRPD-ROF2020: Development of a Point-of-Care Platform for HIV Viral Load Testing

A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome (ARDS) Secondary to Coronavirus Disease 2019 (COVID-19)

Cultivable commensal spores in C. difficile infection

Gary Wang-IPA Agreement-Sidhu

A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults with Different Rabies Exposure Risks

A Phase 3, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection

Gary Wang IPA agreement (Joan Whitlock )

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection